Deslotine

Indonesia • Dexa Medica

Indikasi

Rinitis alergi
Tablet desloratadine 5 mg diindikasikan untuk meringankan gejala-gejala nasal dan non-nasal rinitis alergi (termasuk rinitis alergi yang intermiten dan persisten) pada pasien usia 12 tahun atau lebih).

Urtikaria
Tablet desloratadine 5 mg diindikasikan untuk meringankan gejala pruritus, mengurangi dan memperkecil area gatal pada pasien urtikaria usia 12 tahun atau lebih.

Komposisi

Desloratadine 5 mg

Kemasan

3 strip berisi masing-masing 10 tablet

Bentuk Sediaan

Tablet

Klasifikasi ATC

R06A

Perhatian

Alkohol
Konsultasikan ke Dokter Anda
Keamanan item ini untuk digunakan bersamaan dengan alkohol belum ditetapkan.
Alat Berat
Hati-Hati
Item ini mungkin tidak aman digunakan saat mengoperasikan alat berat. Gunakan dengan hati-hati dan setelah berkonsultasi dengan dokter.
Masa Kehamilan
Konsultasikan ke Dokter Anda
Keamanan item ini untuk digunakan selama masa kehamilan belum ditetapkan.
Menyusui
Tidak Direkomendasikan
Item ini tidak aman digunakan selama menyusui.

Dosis

Up to 12 Years

The safety and effectiveness of desloratadine tablets in pediatric patients under 12 years of age have not been established.

12 to 65 Years Old

The recommended dose is 5 mg (one tablet) once daily.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks):
Should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.

Persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks):
Continued treatment may be proposed to the patients during the allergen exposure periods.

65 Years Old and Above

In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks):
Should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.

Persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks):
Continued treatment may be proposed to the patients during the allergen exposure periods.

Patients with Impaired Hepatic Function

A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.

Patients with Impaired Renal Function

A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.